Pharmacological exploitation of neurotrophins and their receptors to develop novel therapeutic approaches against neurodegenerative diseases and brain trauma
Ioannis Charalampopoulos · Professor of Pharmacology, Medical School, University of Crete & Affiliated Researcher, Institute of Molecular Biology & Biotechnology (IMBB), Foundation for Research and Technology Hellas (FORTH)
Fri, Mar 7, 2025 · 14:30 UTC
Neurotrophins (NGF, BDNF, NT-3) are endogenous growth factors that exert neuroprotective effects by preventing neuronal death and promoting neurogenesis. They act by binding to their respective high-affinity, pro-survival receptors TrkA, TrkB or TrkC, as well as to p75NTR death receptor. While these molecules have been shown to significantly slow or prevent neurodegeneration, their reduced bioavailability and inability to penetrate the blood-brain-barrier limit their use as potential therapeutics. To bypass these limitations, our research team has developed and patented small-sized, lipophilic